Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Gemcitabine (Primary) ; Motixafortide (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus First in man; Therapeutic Use
  • Acronyms Chemo4MetPanc

    • Most Recent Events

    • 04 Jun 2024 Trial design evaluating the preliminary safety and efficacy ofMotixafortide (CXCR4i), Cemiplimab (aPD1), Gemcitabine, and Nab-paclitaxel (MCGN) in 11 patients with treatment-naive mPDAC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 24 May 2024 According to a BioLineRx media release, Updated results from this trial was accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4, 2024 in Chicago, Illinois.
    • 28 Feb 2024 According to a BioLineRx media release,Findings from the single-arm pilot from this study will be shared by Dr. Manji at the 10th Annual Immuno-Oncology (IO) 360 Summit in Brooklyn, New York on Thursday, February 29, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top